Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 4, 2024
Data Byte
FDA’s September approvals include firsts for schizophrenia, Niemann-Pick
Subcutaneous formulations of Tecentriq and Ocrevus also among month’s seven new product approvals
BioCentury | Aug 30, 2024
Data Byte
Nine PDUFA dates on FDA’s agenda in September
Decision on Zevra’s arimoclomol follows positive AdCom vote
BioCentury | Aug 17, 2023
Emerging Company Profile
How Abcuro is targeting specific T cells to treat a rare muscle-wasting disease
Crossovers back company in $155M round to advance KLRG1 program for inclusion body myositis
BioCentury | Jan 7, 2022
Distillery Therapeutics
Blocking atypical necroptosis in retinal pigment epithelium for AMD
BioCentury | Nov 4, 2021
Data Byte
Five newcos developing iPS cell-derived therapies for cancer
The biotechs are turning iPS cells into NK, T, B cells and macrophages
BioCentury | Mar 29, 2021
Product Development
March 29 Quick Takes: Humanigen mAb meets COVID endpoint; plus Merck, Wave, Celldex, Ionis, Orphazyme and uniQure
Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized
BioCentury | Dec 31, 2020
Regulation
Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis
Chi-Med’s surufatinib approved in ChinaChina’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda
BioCentury | Sep 17, 2020
Product Development
Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies
Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT)
BioCentury | Apr 3, 2020
Distillery Therapeutics
Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma
BioCentury | Nov 21, 2019
Tools & Techniques
Measuring real-time PK/PD by monitoring aberrant chaperone activity
Measuring PK/PD in real time by selectively targeting protein networks
Items per page:
1 - 10 of 103